SOCRA - Society of Clinical Research Associates Adverse Event Safety Reporting Questions and Answers

Question 1

A subject in a clinical trial for a new hypertension drug experiences a severe headache, is hospitalized overnight for observation, and is discharged the next day with a diagnosis of a migraine.
The event resolves.
How should the site staff classify this event?

Accepted Answer

A Serious Adverse Event (SAE) because it resulted in inpatient hospitalization.

Answer

A non-serious Adverse Event because it resolved completely.

Answer

Not an Adverse Event because it was diagnosed as a common migraine.

Answer

An unexpected adverse event that does not require expedited reporting.

Question 2

According to 21 CFR 312.32, what is the maximum timeframe within which a sponsor must report an unexpected fatal or life-threatening suspected adverse reaction to the FDA?

Accepted Answer

7 calendar days after the sponsor's initial receipt of the information.

Answer

15 calendar days after the sponsor's initial receipt of the information.

Answer

10 working days after the site reports the event to the sponsor.

Answer

24 hours after becoming aware of the event.

Question 3

Which of the following is a primary responsibility of the Principal Investigator regarding adverse event management?

Accepted Answer

To document all adverse events and report them to the sponsor according to the protocol-specified timelines and procedures.

Answer

To report all Serious Adverse Events (SAEs) directly to the FDA within 24 hours.

Answer

To report only unexpected and related adverse events to the Institutional Review Board (IRB).

Answer

To determine the final causality of an event independently of the sponsor's medical monitor.

Question 4

A subject in a trial for an investigational antidepressant reports developing a mild rash two weeks after starting the drug. The subject has a known history of seasonal allergies and recently started using a new laundry detergent. In assessing this adverse event, what is the MOST critical determination the investigator must make for safety reporting purposes?

Accepted Answer

The likelihood that the event is related to the investigational product (causality).

Answer

Whether the event meets the criteria for 'serious.'

Answer

The exact date the new laundry detergent was first used.

Answer

If the event needs to be reported to the FDA via MedWatch by the site.

Question 5

A sponsor is required by 21 CFR 312.32 to submit an IND safety report to the FDA and all participating investigators for which type of event?

Accepted Answer

A suspected adverse reaction that is both serious and unexpected.

Answer

Any Serious Adverse Event (SAE) that occurs at any study site, regardless of causality.

Answer

Any adverse event that leads to a participant's withdrawal from the study.

Answer

Only for adverse events that are both fatal and definitively related to the investigational drug.

Question 6

In the context of clinical trial safety reporting, which of the following best defines an 'unexpected' adverse reaction?

Accepted Answer

An adverse reaction, the nature or severity of which is not consistent with the applicable product information, such as the Investigator's Brochure.

Answer

A serious adverse event that occurs with a greater frequency than previously reported.

Answer

An adverse event that is not listed in the clinical trial protocol as a potential risk.

Answer

Any adverse reaction that results in a subject requiring an unscheduled hospital visit.

A subject in a clinical trial for a new hypertension drug experiences a severe headache, is hospitalized overnight for observation, and is discharged the next day with a diagnosis of a migraine.The event resolves.How should the site staff classify this event?

A subject in a clinical trial for a new hypertension drug experiences a severe headache, is hospitalized overnight for observation, and is discharged the next day with a diagnosis of a migraine.
The event resolves.
How should the site staff classify this event?